☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - January 2015

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Aztreonam lysine (Cayston®) has been accepted for restricted as suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged six years and older. Use is limited to cases where inhaled colistimethate sodium and inhaled tobramycin are not tolerated or providing an unsatisfactory therapeutic benefit. It is also contingent on the continued availability of a Patient Access Scheme (PAS) that improves the cost effectiveness.

Brimonidine (Mirvaso®) has been accepted for restricted use in the symptomatic treatment of facial erythema of rosacea in adult patients. The restriction limits use to patients with moderate to severe persistent facial erythema associated with rosacea.

Canagliflozin plus metformin (Vokanamet®) has been accepted for restricted use in type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control. The restriction limits use of this product to patients where combination of canagliflozin and metformin is an appropriate choice of therapy.

Olodaterol (Striverdi®) has been accepted for use as maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - January 2015' on Email Share 'SMC Update - January 2015' on Delicious Share 'SMC Update - January 2015' on Digg Share 'SMC Update - January 2015' on Facebook Share 'SMC Update - January 2015' on reddit Share 'SMC Update - January 2015' on Twitter


No Comments to “SMC Update - January 2015”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.